NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Bharat Biotech ends its Brazil agreement. What went wrong?
    Bharat Biotech ends its Brazil agreement. What went wrong?
    1/6
    India 3 min read

    Bharat Biotech ends its Brazil agreement. What went wrong?

    By Sagar
    Jul 24, 2021
    06:53 pm
    Bharat Biotech ends its Brazil agreement. What went wrong?
    What went wrong with Indian firm Bharat Biotech's Brazil deal? An explanation.

    Bharat Biotech on Friday announced the termination its agreement with two foreign firms for the supply of COVAXIN to Brazil. Following that, Brazil canceled the proposed clinical trails of the vaccine in that country. These are the latest developments in a series of reactions after the Brazilian government suspended the $324 million deal with the Indian firm amid corruption allegations. What exactly went wrong?

    2/6

    What was the deal all about?

    In November last year, Bharat Biotech entered into an agreement with Precisa Medicamentos and Envixia Pharmaceuticals LLC for the licensing, distribution, and clinical trials of COVAXIN in Brazil. Precisa is based in Brazil while Envixia is registered in Dubai, UAE. Under the deal worth $324 million, Bharat Biotech was supposed to export 20 million doses of the Indian-made vaccine to the South American country.

    3/6

    What are the allegations about the deal?

    The Brazilian government, led by President Jair Bolsonaro, has been facing allegations of corruption connected to this deal. Officials from the country's Health Department alleged that they were under pressure from higher authorities to clear the deal, which appeared suspicious to them. It was also alleged the deal was being pursued even though Pfizer and other vaccines were available at cheaper rates than COVAXIN.

    4/6

    What does the Brazilian government say?

    The sensational corruption allegations have dominated the Brazilian news media over the past few weeks and a federal investigation is currently underway into the matter there. Bolsonaro and his aides, however, have denied any wrongdoing in the deal. "We didn't spend one cent on COVAXIN. We didn't receive one dose of COVAXIN. What sort of corruption is this?" Bolsonaro had earlier said.

    5/6

    What does Bharat Biotech say?

    Bharat Biotech, which has been credited and praised in India for developing the country's first indigenous coronavirus jab, has also rubbished the allegations of corruption. "We strongly refute and deny any kind of allegation or implication of any wrongdoing whatsoever with respect to the supply of COVAXIN," the company had said in a statement last month as the controversy unfolded.

    6/6

    What happens to COVAXIN's approval in Brazil now?

    Bharat Biotech has said that despite the deal suspension, it will continue to work with the Brazilian health regulator to complete the regulatory approval process in the country. "Based on the communication made by Bharat Biotech, ANVISA will reassess the processes underway at the agency and adopt the relevant measures," Brazil's health regulator has said in a statement.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Brazil
    Jair Bolsonaro
    Bharat Biotech
    COVAXIN
    Coronavirus Vaccine

    Brazil

    Copa America: Brazil beat Chile, will face Peru in semi-finals Chile
    Deck cleared for import of COVAXIN, Sputnik V into Brazil COVID-19 Vaccine
    Copa America 2021: Maracana stadium to host the final Football
    Countries worldwide hit new records for coronavirus cases, deaths India

    Jair Bolsonaro

    Coronavirus vaccine could turn you into 'crocodile': Brazil's President Pfizer
    Coronavirus: Brazil records biggest spike in COVID-19 cases, deaths COVID-19
    Coronavirus: Hospitals in danger of collapse in Brazil's Sao Paulo Brazil
    On Hydroxychloroquine, Trump ditches threatening tone, says 'Modi was great' Narendra Modi

    Bharat Biotech

    Bharat Biotech commits to supply 500mn COVAXIN doses to Centre Coronavirus
    Bharat Biotech enters contract manufacturing deal for COVAXIN drug substance COVID-19 Vaccine
    COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech COVID-19
    Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil Vaccine

    COVAXIN

    COVID-19 vaccines for children likely by September, says AIIMS chief Randeep Guleria
    Government to procure 66 crore doses of Covishield, COVAXIN COVID-19
    Zydus vaccine for 12-18-year-olds from September, says expert panel chief Zydus Cadila
    Seven EU nations, Switzerland approve India-made Covishield for 'Green Pass' European Union Intellectual Property Office (EUIPO)

    Coronavirus Vaccine

    European drug regulator approves Moderna COVID-19 vaccine, Spikevax, for 12-17-year-olds Europe
    Can fully vaccinated people develop long COVID? Health & Wellness
    Half of Australians under lockdown again as COVID-19 cases surge Australia
    No sign of Pfizer, Moderna vaccines in breast milk: Study Pfizer
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023